7 recruiting, 5 active not recruiting. 8 Phase 1, 5 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 5, Active not recruiting 3 |
| Phase 2 | 5 | Active not recruiting 3, Recruiting 2 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow IDEAYA Biosciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 450 | 2026-09-01 | 2026-09-15 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors IDE574, Fulvestrant injection - ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | IDEAYA Biosciences | 160 | 2026-03-17 | 2026-06-16 |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types IDE034 - Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer | Phase 1 | Recruiting | IDEAYA Biosciences | 150 | 2026-02-24 | 2026-06-18 |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma Darovasertib, Primary Local Therapy - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 520 | 2026-01-25 | 2026-05-06 |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer IDE849, durvalumab, IDE161 - Small-cell Lung Cancer, Neuroendocrine Carcinomas | Phase 1 / Phase 2 | Recruiting | IDEAYA Biosciences | 262 | 2025-10-14 | 2026-07-09 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK4418959, PD-1 inhibitor - Neoplasms, Colorectal, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2024-12-13 | 2026-02-02 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Darovasertib - Uveal Melanoma | Phase 2 | Active not recruiting | IDEAYA Biosciences | 160 | 2023-07-03 | 2026-03-16 |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors IDE-161, Pembrolizumab - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 | Active not recruiting | IDEAYA Biosciences | 216 | 2023-04-18 | 2026-07-13 |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion IDE397, Sacituzumab govitecan - Solid Tumor | Phase 1 | Active not recruiting | IDEAYA Biosciences | 169 | 2021-04-14 | 2026-04-09 |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions IDE196, Binimetinib, Crizotinib - Metastatic Uveal Melanoma, Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | IDEAYA Biosciences | 336 | 2019-06-28 | 2026-06-08 |
Colorectal Neoplasms (5) · Uveal Melanoma (5) · Endometrial Neoplasms (3) · Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Squamous Cell Carcinoma (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related (1)
Crizotinib (3) · pembrolizumab (2) · Carboplatin (1) · Dacarbazine (1) · Fulvestrant (1) · Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · Nivolumab (1) · Protein Kinase C (1) · binimetinib (1) · durvalumab (1) · sacituzumab govitecan (1)
United States (12) · Australia (6) · Canada (5) · France (4) · Germany (4) · Netherlands (4) · Spain (4) · Belgium (3) · Italy (3) · Israel (2) · Poland (2) · South Korea (2) · Switzerland (2) · United Kingdom (2) · Austria (1)
Jasgit Sachdev, MD (2) · Darrin Beaupre, MD,PhD (1) · Edward Chan, MD (1) · George Cole Jr., MD (1) · Hetal Patel, MD, MSHS, CHCQM (1)